UCB News

CANCER RESEARCH UK SIGNS MULTI-PROJECT COLLABORATION WITH UCB TO ADVANCE ONCOLOGY ANTIBODY CANDIDATES

Brussels (Belgium), and London (UK) 9 March 2023 - Cancer Research UK, the world's largest charitable funder of cancer research, and UCB (EURONEXT BRUSSELS: UCB), a global biopharmaceutical company, today announced a clinical development collaboration to advance two of UCB's investigational oncology antibody candidates through clinical trials.

The collaboration focuses on the development of two investigational antibody candidates, UCB6114 and UCB4594 by bringing together the oncology-focused translational research and clinical development capabilities of Cancer Research UK, and UCB's renowned antibody discovery expertise. If successful in clinical trials the investigational candidates may have the potential to offer cancer patients access to new targeted treatment options. UCB6114 is a potential first-in-class antibody targeting gremlin-1, a glycoprotein secreted by the tumour stroma[1]*. UCB4594 is an antibody targeting the immune checkpoint, human leukocyte antigen G, also known as HLA-G.

Under the terms of the collaboration, Cancer Research UK's Centre for Drug Development will appoint the chief clinical and scientific investigators, and will lead the design, preparation, sponsorship and delivery of Phase 1/2 clinical trials for both UCB antibody candidates. UCB will continue to manufacture both investigational antibody candidates, complete the ongoing UCB6114 clinical study (ONC001) and perform other supporting activities. UCB will retain exclusive rights to further develop and commercialise both assets and will receive a licence to the results of the clinical trials from Cancer Research UK in return for undisclosed success-based milestone and royalty payments.

Dr Nigel Blackburn, Director Cancer Research UK's Centre for Drug Development, said:

"As funders of much of the world-class cancer research and innovation happening in the UK, we are able to offer our unparalleled access to some of the best oncology expertise and clinical development capabilities to our commercial partners."

"We are delighted to be collaborating with UCB to progress not one, but two novel oncology antibodies and here at the Centre for Drug Development we are looking forward to progressing these programmes through early clinical development."

Dhaval Patel, chief scientific officer of UCB, said:

"UCB's strong research productivity together with our antibody expertise and desire to better understand and target the drivers of disease, has resulted in two novel and potentially disruptive candidates in oncology."

"As these candidates move forward, we are happy to enter this collaboration with Cancer Research UK where they will bring world leading oncology expertise and access to a large network of clinical oncologists who can enable the clinical trials."

Financial details of the partnership were not disclosed.

Notes to editor:

* The tumour stroma is composed of extracellular matrix and specialized connective tissue cells, including fibroblasts and mesenchymal stromal cells[2].

References

1. Sarker D, Banerji U, Blagden SP, et al. A multi-modular phase I/II study of UCB6114, a first-in-class, fully human IgG4P anti-Gremlin-1 monoclonal antibody, as monotherapy and in combination with mFOLFOX6 or trifluridine/tipiracil, for patients with advanced gastrointestinal (GI) tumors. J Clin Oncol. 2022;40(4):Suppl.TPS221.
2. Valkenburg KC, de Groot AE, Pienta KJ. Targeting the tumour stroma to improve cancer therapy. Nat Rev Clin Oncol. 2018;15:366-381.

For media enquiries contact

Ellie Bennett in the Cancer Research UK press office on 020 3469 5370 or, out of hours, on 07884 466 868.

Antje Witte Investor Relations (UCB) on +32.2.559.94.14 or email antje.witte@ucb.com

Laurent Schots, Corporate Communications (UCB) on +32.2.559.92.64 or email laurent.schots@ucb.com

Scott Fleming, R&D Communications (UCB) on +447702777378 or email scott.fleming@ucb.com

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 8 700 people in approximately 40 countries, the company generated revenue of € 5.5 billion in 2022. UCB is listed on Euronext Brussels (symbol: UCB).

About Cancer Research UK's Centre for Drug Development

Cancer Research UK has an impressive record of developing novel treatments for cancer. The Cancer Research UK Centre for Drug Development has been pioneering the development of new cancer treatments for 25 years, taking over 140 potential new anti-cancer agents into clinical trials in patients. It currently has a portfolio of 21 new anti-cancer agents in preclinical development, Phase I or early Phase II clinical trials. Six of these new agents have made it to market including temozolomide for brain cancer, abiraterone for prostate cancer and rucaparib for ovarian cancer. Two other drugs are in late development Phase III trials.

Forward looking statements - UCB

This press release may contain forward-looking statements including, without limitation, statements containing the words "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will", "continue" and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management. All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to differ materially from those that may be expressed or implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: the global spread and impact of COVID-19, changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of

future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, product liability claims, challenges to patent protection for products or product candidates, competition from other products including biosimilars, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws, and hiring and retention of its employees. There is no guarantee that new product candidates will be discovered or identified in the pipeline, will progress to product approval or that new indications for existing products will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans. So far, the complexity of the human body cannot be reproduced in computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has varied in the past and UCB expects similar unpredictability going forward. Products or potential products, which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences disputes between the partners or may prove to be not as safe, effective or commercially successful as UCB may have believed at the start of such partnership. UCB's efforts to acquire other products or companies and to integrate the operations of such acquired companies may not be as successful as UCB may have believed at the moment of acquisition. Also, UCB or others could discover safety, side effects or manufacturing problems with its products and/or devices after they are marketed. The discovery of significant problems with a product similar to one of UCB's products that implicate an entire class of products may have a material adverse effect on sales of the entire class of affected products. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment, including pricing pressure, political and public scrutiny, customer and prescriber patterns or practices, and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement activities and outcomes. Finally, a breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of UCB's data and systems.

Given these uncertainties, you should not place undue reliance on any of such forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labelling in any market, or at any particular time, nor can there be any guarantee that such products will be or will continue to be commercially successful in the future.

UCB is providing this information, including forward-looking statements, only as of the date of this press release and it does not reflect any potential impact from the evolving COVID-19 pandemic, unless indicated otherwise. UCB is following the worldwide developments diligently to assess the financial significance of this pandemic to UCB. UCB expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations.

Additionally, information contained in this document shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any offer, solicitation or sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such jurisdiction.